Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2

Tocilizumab is an IL‐6 receptor antagonist with the ability to suppress the cytokine storm in critically ill patients infected with severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2). We evaluated patients treated with tocilizumab for a SARS‐CoV‐2 infection who were admitted between March...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrak, Russell M., Skorodin, Nathan C., Van Hise, Nicholas W., Fliegelman, Robert M., Pinsky, Jonathan, Didwania, Vishal, Anderson, Michael, Diaz, Melina, Shah, Kairav, Chundi, Vishnu V., Hines, David W., Harting, Brian P., Sidwha, Kamo, Yu, Brian, Brune, Paul, Owaisi, Anjum, Beezhold, David, Kent, Joseph, Vais, Dana, Han, Alice, Gowda, Neethi, Sahgal, Nishi, Silverman, Jan, Stake, Jonathan, Nepomuceno, Jenie, Heddurshetti, Renuka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604239/
https://www.ncbi.nlm.nih.gov/pubmed/32918792
http://dx.doi.org/10.1111/cts.12894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604239/
https://www.ncbi.nlm.nih.gov/pubmed/32918792
http://dx.doi.org/10.1111/cts.12894

Ejemplares similares